DOCSLIB.ORG

Congress Abstracts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Congress Abstracts EAPC ONLUS Abstracts of the 9th Congress of the European Association for Palliative Care (EAPC) Résumés du 9ème Congrès de l’Association Européenne de Soins Palliatifs Aachen, Germany, 8–10 April 2005 Aix la Chapelle, Allemagne, 8–10 avril 2005 ABSTRACTS RÉSUMÉS EAPC Instituto Nazionale Dei Tumori Via Venezian 1 20133 Milano ITALIA Tel: +39 02 2390 3390. Fax: +39 02 2390 3393. email: [email protected] www.eapcnet.org Published by Hayward Medical Communications, a division of Hayward Group plc, Rosalind Franklin House, The Oaks, Fordham Road, Newmarket CB8 7XN, UK. Publié par Hayward Medical Communications, une division d’Hayward Group plc, Rosalind Franklin House, The Oaks, Fordham Road, Newmarket CB8 7XN, Royaume-Uni. Cover picture: View of the Hague by Pieter Gerard Vertin (1819–1893)/ Bridgeman Art Library Couverture: View of the Hague par Pieter Gerard Vertin (1819–1893)/ Bridgeman Art Library Abstracts of the 9th Congress of the European Association for Palliative Care, Aachen 2005 i Résumés du 9ème Congrès de l’Association Européenne de Soins Palliatifs, Aix la Chapelle 2005 ii Abstracts of the 9th Congress of the European Association for Palliative Care, Aachen 2005 Résumés du 9ème Congrès de l’Association Européenne de Soins Palliatifs, Aix la Chapelle 2005 Scientific Committee CONTENTS Stein Kaasa, Norway, Chair Lukas Radbruch, Germany, Co-Chair Eduardo Bruera, USA Friday 8 April 2005 David Clark, UK Franco De Conno, Italy ABSTRACTS OF INVITED LECTURES Marilène Filbet, France AND ORAL PRESENTATIONS 3 Katalin Hegedus, Hungary Phil Larkin, Ireland ABSTRACTS OF POSTERS 17 Friedemann Nauck, Germany Sheila Payne, UK Saturday 9 April 2005 David Praill, UK Advisory Board to the ABSTRACTS OF INVITED LECTURES Scientific Committee AND ORAL PRESENTATIONS 47 Julia Addington-Hall, UK Johann Baumgartner, Austria ABSTRACTS OF POSTERS 60 Snezana Bosnjak, Croatia William Breitbart, USA Sunday 10 April 2005 Bert Broeckaert, Belgium Cristian Juul Busch, Denmark ABSTRACTS OF INVITED LECTURES Nathan Cherny, Israel AND ORAL PRESENTATIONS 91 Nessa Coyle, USA Kathleen Foley, USA ABSTRACTS OF POSTERS 105 Carl Johan Fürst, Sweden Paul Glard, Australia Index Richard Hain, UK Geoffrey Hanks, UK BY AUTHOR 135 Jo Hockley, UK Christoffer Johansen, Denmark Martina Kern, Germany Eberhard Klaschik, Germany Jacek Luczak, Poland Marco Maltoni, Italy Sebastiano Mercadante, Italy Tatsuya Morita, Japan Monika Müller, Germany Katalin Muszbek, Hungary Mildred Solomon, USA Juan Manuel Nuñez Olarte, Spain Margaret O’Connor, Australia Antonio Pascual Lopez, Spain Jose Pereira, Canada Joseph Porta I Sales, Spain Sylvia Sauter, Sweden René Chaerer, France Per Sjøgren, Denmark Jan Tjernsward, Sweden Floria Strasser, Switzerland Corry Van Tol, the Netherlands Charles F Von Gunten, USA Annette Welshman, UK Furio Zucco , Italy Abstracts of the 9th Congress of the European Association for Palliative Care, Aachen 2005 iii Résumés du 9ème Congrès de l’Association Européenne de Soins Palliatifs, Aix la Chapelle 2005 iv Abstracts of the 9th Congress of the European Association for Palliative Care, Aachen 2005 Résumés du 9ème Congrès de l’Association Européenne de Soins Palliatifs, Aix la Chapelle 2005 FRIDAY 8 APRIL 8 FRIDAY ABSTRACTS OF INVITED LECTURES, ORAL PRESENTATIONS AND POSTERS 8 APRIL 2005 Abstracts of the 9th Congress of the European Association for Palliative Care, Aachen 2005 Résumés du 9ème Congrès de l’Association Européenne de Soins Palliatifs, Aix la Chapelle 2005 Invited lectures and oral presentations 2 Abstracts of the 9th Congress of the European Association for Palliative Care, Aachen 2005 Résumés du 9ème Congrès de l’Association Européenne de Soins Palliatifs, Aix la Chapelle 2005 Invited lectures and oral presentations Abstract number: 1 Abstract number: 3 Abstract number: 5 Presentation type: Invited Presentation type: Invited Presentation type: Invited Poster number: Poster number: Poster number: Curriculum for Palliative Nurse Education “Palliative care – an international Opioid Pharmacogenetics – does it perspective – the observatory”. matter clinically? Phil Larkin, Dept. Palliative Medicine, Galway, IRELAND, Françoise Porchet, Centre Hospitalier Carlos Centeno, Hospital Los Montalvos, Lukas Radbruch, Department of Palliative Universitaire Vaudois CHUV, Lausanne, Salamanca, Spain Medicine, University of Aachen, Germany SWITZERLAND In this session we are going to explain the four The recommendations of the expert working As part of the EAPC TASKFORCE Strategy on lines of work of the EAPC Task Force on group of the European Association for Palliative APRIL 8 FRIDAY Education, a taskforce was identified to prepare development of Palliative Care in Europe: Care (EAPC) has evaluated the level of evidence guidelines that would provide a framework for of the available opioids. Summarizing this palliative nurse education in Europe. This a) Literature review and summary of any evaluation, the efficacy of opioids is well document, recently published by the EAPC, published work about the development of proven. Morphine and other opioids of the offers a plan of action for centres who wish to palliative care in each of the countries. This WHO-steps 2 and 3 are effective for the pursue the development of palliative nurse job is mainly carried out by Javier Rocafort treatment of cancer pain. education and highlights key considerations, with the help of Anthony Greenwood. With the increasing number of available skills and competencies and identifies the b)International survey to boards of the National opioids and application forms individual supportive and inhibitory factors to sound Associations of Palliative Care, seeking differences in the efficacy of these opioids have education for nurses. opinions about the general situation, led to the opinion that the indication for In this workshop, a brief overview of the key strengths and opportunities for palliative care opioids and specific application routes should recommendations will be given, followed by in their country. be decided for the individual patient in the the opportunity for audience participants to c) International survey to an expert within each specific setting. The rationale for this share their experiences of organizing, country, to gather concrete data about the differentiated approach is found in individual facilitating and evaluating education initiatives, state of palliative care service delivery and differences in the efficacy of different opioids, as well as sharing the reality of education for organization in the country. differences in the side effect profile, efficacy nurses within the European context. d)Research on the national Directories of with different pain syndromes such as Services, whether published, printed or neuropathic pain or breakthrough pain, and online. differences with organ dysfunction or failure Abstract number: 2 Also, the present state of the study and our such as renal or hepatic insufficiency. Presentation type: Invited upcoming plans will be explained. With the introduction of new slow release Poster number: application forms in the last years differences in the side effect profile have been postulated. Less Palliative care – an international Abstract number: 4 constipation with transdermal fentanyl, lower perspective: the work of the International Presentation type: Invited incidence of neurotoxic side effects with Observatory on End of Life Care Poster number: oxycodone and lower risk of respiratory depression with buprenorphine have been David Clark, International Observatory on End Opioids pharmacogenetics – does it postulated. Buprenorphine might be of Life Care, Lancaster, GREAT BRITAIN matter clinically? advantageous in renal impairment, as part of the drug is excreted through bile and gut. Founded at Lancaster University in 2003, the Pal Klepstad, Dept. Intensive Care Medicine, Fentanyl or methadone could offer advantages International Observatory on End of Life Care is Trondheim, NORWAY for patients with hepatic impairment. The non- the first ever research and development project opioid activities of some opioids, especially the to concentrate on the comparative analysis of Variability of opioid efficacy caused by genetic reuptake inhibition of monoaminergic hospice and palliative care around the world. variations has been recognized for several years. transmitters and the NMDA-antagonism, have The Observatory is unique in being focussed The most established clinical significant genetic been considered as advantages of tramadol and solely on end of life care and in its emphasis on variability is related to the CYP2D6 enzyme methadone for neuropathic pain. a social science perspective. The aims of the metabolizing codeine to morphine. Slow Using evidence-based criteria, these theses Observatory are: 1. To provide clear and metabolizers of codeine produce less morphine must remain under discussion. It remains accessible research-based information on and have a less pronounced analgesic effect unclear, whether data from animal pain models hospice and palliative care provision in the from codeine. Genetic variability has also been or healthy volunteers can be transferred to international context, incorporating shown to influence on the efficacy of opioids cancer patients. An individually adapted opioid ethnographic, historical and ethical for moderate to severe cancer pain such as therapy, taking pain syndrome, receptor status perspectives as well as health care systems morphine. This genetic variability may be and patient metabolism
Load more

Recommended publications
  • Opioid-Induced Hyperalgesia in Humans Molecular Mechanisms and Clinical Considerations
    SPECIAL TOPIC SERIES Opioid-induced Hyperalgesia in Humans Molecular Mechanisms and Clinical Considerations Larry F. Chu, MD, MS (BCHM), MS (Epidemiology),* Martin S. Angst, MD,* and David Clark, MD, PhD*w treatment of acute and cancer-related pain. However, Abstract: Opioid-induced hyperalgesia (OIH) is most broadly recent evidence suggests that opioid medications may also defined as a state of nociceptive sensitization caused by exposure be useful for the treatment of chronic noncancer pain, at to opioids. The state is characterized by a paradoxical response least in the short term.3–14 whereby a patient receiving opioids for the treatment of pain Perhaps because of this new evidence, opioid may actually become more sensitive to certain painful stimuli. medications have been increasingly prescribed by primary The type of pain experienced may or may not be different from care physicians and other patient care providers for the original underlying painful condition. Although the precise chronic painful conditions.15,16 Indeed, opioids are molecular mechanism is not yet understood, it is generally among the most common medications prescribed by thought to result from neuroplastic changes in the peripheral physicians in the United States17 and accounted for 235 and central nervous systems that lead to sensitization of million prescriptions in the year 2004.18 pronociceptive pathways. OIH seems to be a distinct, definable, One of the principal factors that differentiate the use and characteristic phenomenon that may explain loss of opioid of opioids for the treatment of pain concerns the duration efficacy in some cases. Clinicians should suspect expression of of intended use.
    [Show full text]
  • Ong Edmund W 201703 Phd.Pdf (5.844Mb)
    INVESTIGATING THE EFFECTS OF PROLONGED MU OPIOID RECEPTOR ACTIVATION UPON OPIOID RECEPTOR HETEROMERIZATION by Edmund Wing Ong A thesis submitted to the Graduate Program in Pharmacology & Toxicology in the Department of Biomedical and Molecular Sciences In conformity with the requirements for the degree of Doctor of Philosophy Queen’s University Kingston, Ontario, Canada March, 2017 Copyright © Edmund Wing Ong, 2017 Abstract Opioid receptors are the sites of action for morphine and most other clinically-used opioid drugs. Abundant evidence now demonstrates that different opioid receptor types can physically associate to form heteromers. Owing to their constituent monomers’ involvement in analgesia, mu/delta opioid receptor (M/DOR) heteromers have been a particular focus of attention. Understandings of the physiological relevance of M/DOR formation remain limited in large part due to the reliance of existing M/DOR findings upon contrived heterologous systems. This thesis investigated the physiological relevance of M/DOR generation following prolonged MOR activation. To address M/DOR in endogenous tissues, suitable model systems and experimental tools were established. This included a viable dorsal root ganglion (DRG) neuron primary culture model, antisera specifically directed against M/DOR, a quantitative immunofluorescence colocalizational analysis method, and a floxed-Stop, FLAG-tagged DOR conditional knock-in mouse model. The development and implementation of such techniques make it possible to conduct experiments addressing the nature of M/DOR heteromers in systems with compelling physiological relevance. Seeking to both reinforce and extend existing findings from heterologous systems, it was first necessary to demonstrate the existence of M/DOR heteromers. Using antibodies directed against M/DOR itself as well as constituent monomers, M/DOR heteromers were identified in endogenous tissues and demonstrated to increase in abundance following prolonged mu opioid receptor (MOR) activation by morphine.
    [Show full text]
  • Case Discussions in Palliative Medicine Levorphanol For
    JOURNAL OF PALLIATIVE MEDICINE Volume 21, Number 3, 2018 Case Discussions in Palliative Medicine ª Mary Ann Liebert, Inc. DOI: 10.1089/jpm.2017.0475 Feature Editor: Craig D. Blinderman Levorphanol for Treatment of Intractable Neuropathic Pain in Cancer Patients Akhila Reddy, MD,1,* Amy Ng, MD,1,* Tarun Mallipeddi,2 and Eduardo Bruera, MD1 Abstract Neuropathic pain in cancer patients is often difficult to treat, requiring a combination of several different pharmacological therapies. We describe two patients with complex neuropathic pain syndromes in the form of phantom limb pain and Brown-Sequard syndrome who did not respond to conventional treatments but re- sponded dramatically to the addition of levorphanol. Levorphanol is a synthetic strong opioid that is a potent N- methyl-d-aspartate receptor antagonist, mu, kappa, and delta opioid receptor agonist, and reuptake inhibitor of serotonin and norepinephrine. It bypasses hepatic first-pass metabolism and thereby not subjected to numerous drug interactions. Levorphanol’s unique profile makes it a potentially attractive opioid in cancer pain man- agement. Keywords: Brown-Sequard syndrome; cancer; cancer pain; levorphanol; neuropathic pain; phantom limb pain Introduction changes, structural reorganization of spinal cord and primary somatosensory cortex, and increased sensitization of spinal ne-third of cancer patients who experience pain cord may be the neurological basis for PLP.8,9 Because the Oalso experience neuropathic pain1 and about half the pathophysiology of PLP is not clearly understood, the treat- patients with cancer who suffer from neuropathic pain also ment options are mainly based on clinical experience.9 There have nociceptive pain.2 Most neuropathic pain exists as are case series showing that tramadol and methadone may be mixed pain in combination with nociceptive pain.
    [Show full text]
  • Contents (WELCOME)
    Contents (WELCOME) ................................................................................................................................................ 2 (TERMINOLOGY) ....................................................................................................................................... 4 (SAFETY) ..................................................................................................................................................... 7 (GOLDEN RULES NOT TO BREAK) ...................................................................................................... 11 (PATIENT ASSESSMENT) ....................................................................................................................... 13 (PAIN RELIEF VS FUNCTION/ADL) ..................................................................................................... 15 (ADJUVANT THERAPIES) ...................................................................................................................... 16 (MEDICATION SIDE EFFECTS) ............................................................................................................. 18 (ONGOING THERAPY AND MONITORING) ....................................................................................... 24 (MEDICATION SAFE STORAGE AND DISPOSAL) ............................................................................. 26 (DISCONTINUING OPIOID THERAPY) ................................................................................................ 28 (CO-USE WITH
    [Show full text]
  • Page 1 of 17 10/11/2017 File:///C:/Users/Henadzi.Sobal/Documents
    Page 1 of 17 GOT18-0018. Impact of Clinical Pharmacist Analysis to Clinical Decision-Making for Drug Therapy Management in the Hospital Care Setting Background A deeper understanding of pharmacist clinical decision-making should provide the influence that pharmacists have on patient health care, should guide pharmacy policy and education, should contribute to educating less experienced pharmacists on decision-making processes, should promote more interprofessional work, and should encourage pharmacist decision-making toward the wisest selections of patients’ medication therapy. Purpose The overarching objective of this research study was to document drug therapy decision-making processes of clinical pharmacists in the hostital care setting. The specific aims of this study were to examine the current clinical decision-making of clinical pharmacists in the context of the hospital care clinic setting, to compare and contrast pharmacist clinical decision-making with current decision-making models. Material and methods We used a quasi-randomized design to evaluate a quality improvement project in three hospitals in Kazakhstan. Three audio-taped data collection methods of participant observation and semi-structured interview were utilized and exactly transcribed to provide textual data for analysis. Thematic analysis provided emerging themes of clinical pharmacist-led medication and clinical decision-making which were further subdivided into subsuming themes after much reflection and interpretation of the entire study data. Results Other health professions have identified experienced clinical decision-aking to encompass the Decision Analysis, intuition and pattern recognition. Clinical pharmacists’ clinical decision-making processes are considered in light of other health professionals’ decision-making techniques; however the results show that clinical pharmacists use a different model of clinical decision-making using constant dialogue between two different types of knowledge (objective and context-related).
    [Show full text]
  • PEOLC Provincial Guideline for Treatment Opioid Neurotoxicity
    Guideline for the Treatment of Opioid Neurotoxicity Definition Patients on chronic opioids can develop neuroexcitatory side effects: hyperalgesia (increased sensitivity to pain), cognitive changes (disordered attention and impaired short-term memory), delirium with hallucinations, myoclonus. Etiology This can be due to an opioid dose which is too high for the patient, dehydration and/or renal failure. General Approach Review the medical record (pattern of opioid use and dose escalation, other medications, the presence of electrolyte abnormalities and major organ dysfunction). Whenever medically appropriate, easily treatable causes or exacerbating factors should be corrected (e.g., correct hypomagnesemia). Treatment Strategies 1. Opioid dose reduction. Make sure you are not reducing the opioid dose solely to control side effects at the expense of good pain control. Consider changing the frequency if renal function is impaired (i.e., from q4h to q6h) 2. Rotate to a dissimilar opioid. Rotating to a lower dosage of a structurally dissimilar opioid will often reduce neuroexcitatory effects within 24 – 48 hours, while achieving comparable pain control. Rotation is especially important in patients with opioid-induced hyperalgesia. Decrease the morphine equianalgesic dose by 25 – 50% when switching to a new opioid (to account for incomplete cross tolerance). Use immediate release formulations until a new stable dose is achieved. To rotate a patient to a new opioid, use the following equianalgesic ratios (see chart on page 3): Oral Routes: Morphine 10 mg = Oxycodone 5 mg = Codeine 100 mg = Hydromorphone 2 mg Oral to Subcutaneous Routes: Ratio (PO) 2:1 (IV/SC) i.e., Morphine 10mg PO = Morphine 5mg IV/subcut or Hydromorphone 10mg PO = Hydromorphone 5mg IV/subcut April 22, 2020 Seniors Health, Palliative and End of Life Care A Caregiver’s Resource for Caring for your Loved One at Home during COVID-19 • 2 Transdermal Fentanyl/ Fentanyl infusion: There are various accepted methods.
    [Show full text]
  • Opioid Tolerance and Hyperalgesia
    Med Clin N Am 91 (2007) 199–211 Opioid Tolerance and Hyperalgesia Grace Chang, MD, MPH, Lucy Chen, MD, Jianren Mao, MD, PhD* Massachusetts General Hospital Pain Center, Division of Pain Medicine, Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA Opioids are well recognized as the analgesics of choice, in many cases, for treating severe acute and chronic pain. Exposure to opioids, however, can lead to two seemingly unrelated cellular processes, the development of opi- oid tolerance and the development of opioid-induced pain sensitivity (hyper- algesia). The converging effects of these two phenomena can significantly reduce opioid analgesic efficacy, as well as contribute to the challenges of opioid management. This article will review the definitions of opioid toler- ance (particularly to the analgesic effects) and opioid-induced hyperalgesia, examine both the animal and human study evidence of these two phenom- ena, and discuss their clinical implications. The article will also differentiate the phenomena from other aspects related to opioid therapy, including physical dependence, addiction, pseudoaddiction, and abuse. Opioid tolerance and opioid-induced hyperalgesia Opioid tolerance is a phenomenon in which repeated exposure to an opi- oid results in decreased therapeutic effect of the drug or need for a higher dose to maintain the same effect [1]. There are several aspects of tolerance relevant to this issue [2]: Innate tolerance is the genetically determined sensitivity, or lack thereof, to an opioid that is observed during the first administration. Acquired tolerance can be divided into pharmacodynamic, pharmacokinetic, and learned tolerance [3]. Pharmacodynamic tolerance refers to adaptive changes that occur within systems affected by the opioid, such as opioid-induced changes in receptor density or desensitization of opioid receptors, such that response to a given * Corresponding author.
    [Show full text]
  • Revisiting Old Friends: Update on Opioid Pharmacology
    VOLUME 37 : NUMBER 2 : APRIL 2014 ARTICLE Revisiting old friends: update on opioid pharmacology Ben Snyder Advanced trainee SUMMARY General medicine and clinical pharmacology Opioids are commonly prescribed for pain due to malignant and non-malignant diseases. They are effective, but have potentially fatal toxicities. Key words Opioid analgesics act as agonists at the mu opioid receptor. Some products combine a mu analgesia, codeine, agonist and antagonist, but there are limitations to their use. morphine, naloxone, pharmacogenetics Genetic variations may explain why people respond differently to opioids. Some patients have an inadequate response to codeine because they poorly metabolise it to morphine. Aust Prescr 2014;37:56–60 Switching from one opioid to another is sometimes necessary, but must be done carefully. Use conversion tables as a reference, but be aware of their limitations. Introduction These cellular events can inhibit neuronal firing and Opioid drugs are prescribed for acute and chronic neurotransmitter release. pain of moderate or severe intensity arising from both All of the opioid analgesics act as agonists at the mu malignant and non-malignant diseases (see Table).1,2 receptor. Mu activation inhibits the ascending pain They benefit many patients, but there are increasing pathway, which includes neurons passing through the numbers of unintentional fatal overdoses.3 A clinician dorsal horn of the spinal cord, brainstem, thalamus weighing up the potential benefits and harms of and cortex. Mu agonists also activate the inhibitory opioids is also confronted with an array of newly descending pain pathway, which involves sites in the available drugs and formulations. Understanding the brainstem.
    [Show full text]
  • Ultra Low Dose Naltrexone - for Lower Opiate Tolerance - Res
    Ultra Low Dose Naltrexone - For Lower Opiate Tolerance - Res... https://www.khemcorp.com/ultra-low-dose-naltrexone-for-lowe... SHOPPING CART You have 0 items Home Online Shop ∠ Learn & How To ∠ Contact Us – You – ∠ About Us & FAQ ∠ Search Ultra Low Dose Naltrexone – For Lower Opiate Tolerance – Research Products Summary Oxytocin Nasal Spray Posted by Anonymous on November 04, 2015 / Posted in Khemcorp Originals, Reverse Tolerance 60ml 6500 IU V2.0 (For Autism, Social Anxiety and Empathy) $49.99 Synaptic Focus 6000mg (For ADHD, Procrastination, Brain Fog) $49.99 What is Naltrexone? OASIS Pro (CES Contents [hide] Device) (Electric Stimulation Therapy) Naltrexone is described as a 1 What is Naltrexone? $450.00 substituted oxymorphone, it’s 2 What is Ultra Low Dose Naltrexone? active metabolites are antagonists 3 How Does Ultra Low Dose Naltrexone Potentiate Opioids? at the u-opioid receptor (MOR), 4 How Does ULDN Work to Reverse Opiate tolerance or tolerances of Other Drugs? Q-wiz Suite k-opioid receptor (KOR), and the 5 Why Ultra Low Dose Naltrexone, rather than Low Dose or even just Naltrexone? $2,795.00 $2,515.50 o-opioid receptor (DOR). 6 What’s the Dosage and How Should It Be Taken? 7 What’s the Upper Ceiling? Naltrexone’s primary use (in 8 Potential Interactions and Risks to Watch Out normal doses) is in the 9 Bonus Information management of opioid and 10 Research References Q-wiz Elemental alcohol dependency. It is also 11 Related Posts often used to reduce $995.00 $895.50 Benzodiazepine withdrawal symptoms as both Benzodiazepines and alcohol rely on agonizing GABA receptors, which is also why addiction to alcohol or benzodiazepines are also notoriously difficult to treat.
    [Show full text]
  • Opioid Therapy in Acute and Chronic Pain 2018, 00(0) 1–12 C 2018, the American College of Clinical Pharmacology DOI: 10.1002/Jcph.1276
    Core Entrustables in Clinical Pharmacology: Pearls for Clinical Practice The Journal of Clinical Pharmacology Opioid Therapy in Acute and Chronic Pain 2018, 00(0) 1–12 C 2018, The American College of Clinical Pharmacology DOI: 10.1002/jcph.1276 Anne N. Nafziger, MD, PhD, MHS, FCP,1,2 and Robert L. Barkin, PharmD, MBA, FCP3,4 Abstract This is an article in the Core Entrustables in Clinical Pharmacology series that describes opioid therapy in acute and chronic pain. Opioid use during surgical procedures or anesthesia is not discussed. Basic pharmacokinetic and pharmacodynamic properties of opioids are reviewed. The safe and effective use of opioids, including clinical assessment and treatment plan, equianalgesic dosing, opioid rotation, opioid risks and side effects, and clinical adherence monitoring are discussed. Individualized opioid use can be a safe and effective component of a patient-specific multimodal treatment plan for acute or chronic pain. Adverse effects and risks can be prevented or effectively managed when anticipated and recognized. The article is followed by 4 clinical vignettes with discussions. Keywords Analgesics, Opioid, Pain management, Opioid-related disorders, Drug therapy, Treatment outcome After reading this article, the reader will be familiar strategy program) are among those organizations that with the common classes of opioid agonists and partial have issued guidelines to assist with opioid prescription agonists, the basics of pharmacokinetics and pharma- in the outpatient setting.3–8 codynamics of opioids, the risks of opioid therapy, and A serious public health problem has developed in the requirements for safe and effective use of opioids the United States because of the misuse, abuse, and in acute and chronic pain.
    [Show full text]
  • Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia
    A publication of the PHARMACEUTICAL SERVICES DIVISION AND THE CLINICAL RESEARCH CENTRE MINISTRY OF HEALTH MALAYSIA MALAYSIAN STATISTICS ON MEDICINES 2008 Edited by: Lian L.M., Kamarudin A., Siti Fauziah A., Nik Nor Aklima N.O., Norazida A.R. With contributions from: Hafizh A.A., Lim J.Y., Hoo L.P., Faridah Aryani M.Y., Sheamini S., Rosliza L., Fatimah A.R., Nour Hanah O., Rosaida M.S., Muhammad Radzi A.H., Raman M., Tee H.P., Ooi B.P., Shamsiah S., Tan H.P.M., Jayaram M., Masni M., Sri Wahyu T., Muhammad Yazid J., Norafidah I., Nurkhodrulnada M.L., Letchumanan G.R.R., Mastura I., Yong S.L., Mohamed Noor R., Daphne G., Kamarudin A., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Omar I., Zoriah A., Fong Y.Y.A., Nusaibah A.R., Feisul Idzwan M., Ghazali A.K., Hooi L.S., Khoo E.M., Sunita B., Nurul Suhaida B.,Wan Azman W.A., Liew H.B., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Asmah J., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I., Ghazali I., Wan Abu Bakar Y., Wan Hamilton W.H., Ravichandran J., Zaridah S., Wan Zahanim W.Y., Kannappan P., Intan Shafina S., Tan A.L., Rohan Malek J., Selvalingam S., Lei C.M.C., Ching S.L., Zanariah H., Lim P.C., Hong Y.H.J., Tan T.B.A., Sim L.H.B, Long K.N., Sameerah S.A.R., Lai M.L.J., Rahela A.K., Azura D., Ibtisam M.N., Voon F.K., Nor Saleha I.T., Tajunisah M.E., Wan Nazuha W.R., Wong H.S., Rosnawati Y., Ong S.G., Syazzana D., Puteri Juanita Z., Mohd.
    [Show full text]
  • Stanford Acute Pain Management Resident Rotation Syllabus Version 2019-2020 Updated February 19, 2019 Table of Contents
    Stanford Acute Pain Management Resident Rotation Syllabus Version 2019-2020 Updated February 19, 2019 http://paincenter.stanford.edu Table of Contents PAIN MANAGEMENT FACULTY ........................................................................................................................ 2 GOALS AND OBJECTIVES ................................................................................................................................ 2 ADVERSE EFFECTS OF PERIOPERATIVE PAIN ........................................................................................... 5 OPIOIDS ............................................................................................................................................................. 7 NEURAXIAL ANALGESIA ................................................................................................................................. 15 REGIONAL ANESTHESIA AND PERIPHERAL NERVE CATHETERS .......................................................... 23 ADJUVANTS ..................................................................................................................................................... 30 OPIATE TOLERANT PATIENTS ....................................................................................................................... 40 CANCER PAIN .................................................................................................................................................. 37 ACUPUNCTURE AND PAIN MANAGEMENT ..................................................................................................
    [Show full text]